Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The recognition that malfunction of the microtubule (MT) associated protein tau is likely to play a defining role in the onset and/or progression of a number of neurodegenerative diseases, including Alzheimers disease, has resulted in the initiation of drug discovery programs that target this protein. Tau is an endogenous MT-stabilizing agent that is highly expressed in the axons of neurons. The MT-stabilizing function of tau is essential for the axonal transport of proteins, neurotransmitters and other cellular constituents. Under pathological conditions, tau misfolding and aggregation results in axonal transport deficits that appear to have deleterious consequences for the affected neurons, leading to synapse dysfunction and, ultimately, neuronal loss. This review focuses on both progress and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function and (B) small molecule inhibitors of tau aggregation. Keywords: Protein-protein interaction, tau, Alzheimer's disease, neurodegenerative tauopathies, microtubule-stabilizing agents, aggregation inhibitors, microtubule, neuronal loss, cyclosporine A, FK506, taxanes, vinca alkaloids, RGD-mimetics, central nervous system, Pick's disease, frontotemporal dementia, neurofibrillary tangles, frontotemporal lobar degeneration, tau-MT complex, phosphorylation, antineoplastic agents, rheumatoid arthritis, psoriasis, paclitaxel, blood-brain barrier, P-glycoprotein, ATP-binding cassette, IDN5109, brain to plasma ratio, TXD258, Larotaxel, ANG1005, Angiopep-2, Epothilones, Ixabepilone, desoxyepothilones, discodermolide, dictyostatin, cyclostreptin, davunetide, N-methyl-D-aspartate, phenothiazines, anthraquinones, N-phenylamines, thiazolyl-hydrazides, rhodanines, quinoxalines, aminothienopyridazines
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“The misfolding of tau is likely to be a stochastic phenomenon [20], which becomes more probable at higher cytosolic tau concentrations.”
BackgroundTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 2×
“Although the exact mechanism(s) underlying tau-mediated neurodegeneration has not been fully elucidated, under pathological conditions, tau malfunctions can lead to synaptic dysfunction and neuronal loss at least in part by causing axonal transport deficits [10,11].”
BackgroundSelf-citationTau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 2×
“Furthermore, a growing number of protein-protein interactions are considered to be potentially druggable targets [3,4,8].”
BackgroundGoedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., & Crowther, R. A. (1996) · Nature · doi:10.1038/383550a0 · Cited by 1,036 · cited 1×
“This situation improved, however, with the discovery that anionic co-factors such as heparin [106] or arachidonic acid [107] induce faster fibrillization kinetics with lower concentrations of tau and truncated fragments thereof.”
BackgroundMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · cited 3×
“NAP is being developed by Allon Therapeutics Inc. (Vancouver, Canada) and is currently in clinical trials for AD and soon will enter clinical trials for progressive supranuclear palsy, an FTLD-Tau disorder with dementia and parkinsonism.”
BackgroundSelf-citationCirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660 · cited 1×
“Indeed, recent studies have shown that Pgp-deficiency at the BBB in an AD mouse model resulted in a marked increase in Aβ deposition [56].”
BackgroundSelective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459 · cited 1×
“believed to be post-translationally regulated, mainly by serine/threonine-directed phosphorylation of tau as higher phosphorylation states of the protein are known to reduce the binding affinity of tau for the MTs [19].”
BackgroundAdvances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440 · cited 1×
“Thus, based on our current understanding of tau-mediated neurodegeneration, a number of potential targets have been identified that could be exploited for therapeutic intervention [22].”
BackgroundSelf-citationZhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413 · cited 2×
“Importantly, the therapeutic potential of MT-stabilizing agents to treat neurodegenerative tauopathies was validated by in vivo efficacy studies conducted in 2005 by the Lee and Trojanowski laboratory [23].”
BackgroundMethodSelf-citationRepeat motifs of tau bind to the insides of microtubules in the absence of taxol
Kar, S., Fan, J., Smith, M. J., Goedert, M., & Amos, L. A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg001 · Cited by 355
Development of tau aggregation inhibitors for alzheimer's disease
Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E., Waldmann, H., & Mandelkow, E. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802621 · Cited by 286 · cited 1×
“Collectively, these screening efforts resulted in the identification of a number of compound classes (Figure 10) that reduce the formation of tau fibrils in vitro [112,113].”
BackgroundPanda, D., Samuel, J. C., Massie, M., Feinstein, S. C., & Wilson, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633508100 · Cited by 280
How Taxol® stabilises microtubule structure
Amos, L. A., & Löwe, J. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)89002-4 · Cited by 248
Buey, R. M., Barasoain, I., Jackson, E., Meyer, A., Giannakakou, P., Paterson, I., Mooberry, S., Andreu, J. M., & Díaz, J. F. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.09.010 · Cited by 231 · cited 1×
“However, these compounds are unable to stabilize MTs in a cellfree tubulin-assembly assay, indicating a different mechanism of action for this class of compounds [100].”
BackgroundVulih-Shultzman, I., Pinhasov, A., Mandel, S., Grigoriadis, N., Touloumi, O., Pittel, Z., & Gozes, I. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129551 · Cited by 219 · cited 1×
“Furthermore, davunetide was found to reduce tau-hyperphosphorylation both in vitro [101] as well as in ADNP+/− mice [103].”
BackgroundCyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites
Buey, R. M., Calvo, E., Barasoain, I., Pineda, O., Edler, M. C., Matesanz, R., Cerezo, G., Vanderwal, C. D., Day, B. W., Sorensen, E. J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio853 · Cited by 156 · cited 1×
“For example, cyclostreptin (FR182877) [88] is the only example that was found to covalently modify tubulin [89,90].”
BackgroundBrunden, K. R., Ballatore, C., Crowe, A., Smith, Lee, V. M.-Y., & Trojanowski, J. Q. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.031 · Cited by 93 · cited 1×
“Collectively, these screening efforts resulted in the identification of a number of compound classes (Figure 10) that reduce the formation of tau fibrils in vitro [112,113].”
BackgroundSelf-citation
Cited by
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
“CONCLUSION In recent years, new PPIs modulators development has been an attractive goal in preclinical studies.(242,243) However, the design of modulators targeting PPIs still faces tremendous challenges.”
BackgroundRole of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects
Barbier, P., Zejneli, O., Martinho, M., Lasorsa, A., Belle, V., Smet-Nocca, C., Tsvetkov, P. O., Devred, F., & Landrieu, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00204 · Cited by 617
Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Heuer, E., F. Rosen, R., Cintron, A., & C. Walker, L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315885 · Cited by 169
Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation
Crowe, A., James, M. J., Lee, V. M.-Y., Smith, A. B., Trojanowski, J. Q., Ballatore, C., & Brunden, K. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436006 · Cited by 143
Self-citationDeveloping therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122
Self-citation
Metadata
- Authors
- Ballatore, C., R. Brunden, K., Q. Trojanowski, J., M.-Y. Lee, V., B. Smith, A., & M. Huryn, D.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-02-01
- Volume
- 11
- Issue
- 3
- Pages
- 317-330
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2125676993
- Cited by
- 44
- References
- 19
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.